A Phase 3 interventional study of Sildenafil citrate in Pulmonary Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 52 sites in 11 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing sildenafil in Hypertension, Pulmonary — 1 open to participants now, 1 under way, none of them phase 3. sildenafil · Hypertension, Pulmonary.
Among the 51 studies testing sildenafil in Hypertension, Pulmonary, this one is the 3rd largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2003, is one of 15 in phase 3, and was the 3rd registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →1 of the 51 studies testing sildenafil in Hypertension, Pulmonary is open now, in 1 country. Recruiting first, the newest first:
University of Utah · Sites in United States
By country, each count listing its studies:
sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 20 · Phase 4 13
First in 2002; this study’s year is marked. 3 started in 2003.
This study's enrollment of 267 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 30 across the 50 interventional studies. Of the 36 that completed or were terminated, 16 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
10 studies in Hypertension, Pulmonary by Viatris Inc.: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 10 studies in Hypertension, Pulmonary by Viatris Inc., this one is the only one that started in 2003, is one of 4 in phase 3, and was the 1st registered.
Viatris Inc.’s Hypertension, Pulmonary studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 51 studies testing sildenafil in Hypertension, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 10 in Hypertension, Pulmonary:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Categorized Change From Baseline in 6-Minute Walking Distance
Number of subjects with categorized change in 6-minute walking distance. Distance that a subject could walk in 6-minutes at a comfortable pace with as many breaks as needed. Performed as close to trough levels of sildenafil as possible (just before dosing; at least 4 hours after the previous dose of study drug). Scores for categorized changes for missing visits were imputed as the worse score of its non-missing neighbors. If a visit was missing and there was no subsequent score, the score was coded to missing.
Time frame: 1 Year, 2 Year, 3 Year
Survival Status
Yearly survival status: number of subjects who survived, discontinued, and died. Analysis includes post-treatment visit data from subjects who discontinued study treatment. Time to death was taken relative to the first dose of study treatment in A1481141, and was censored on the last day the subject was known to be alive in A1481141 or A1481153.
Time frame: 1, 2, 3, 4, and 5 years
Change in Pulmonary Hypertension Criteria for Functional Capacity and Therapeutic Class
Pulmonary hypertension (PH) criteria: Class I: PH without limitation of physical activity (PA) (no undue dyspnea, fatigue, chest pain, near syncope); Class II: PH with slight limitation in PA, comfortable at rest, ordinary PA causes undue dyspnea, fatigue, chest pain, near syncope; Class III: PH with marked limitation in PA, comfortable at rest, less than ordinary activity causes undue dyspnea, fatigue, chest pain or syncope; Class IV: PH with inability to carry out PA without symptoms, signs of right heart failure, dyspnea or fatigue may be present at rest, discomfort increased by any PA.
Time frame: 1 Year, 2 Year, 3 Year
Change From Baseline in Medical Outcomes Study Short Form 36 (SF-36)
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores = better health status. Change from baseline = score at observation minus score at baseline.
Time frame: Baseline, Month 15, Month 27, Month 39
Change From Baseline in European Quality of Life Scale (EuroQol) 5-Dimensions (EQ-5D): Utility Index Score
EQ-5D: subject rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Time frame: Baseline, Month 15, Month 27, Month 39
Change From Baseline in European Quality of Life (EuroQol) Visual Analogue Scale (EQ-5D VAS): Current Health State Score
EQ-5D: subject rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
Time frame: Baseline, Month 15, Month 27, Month 39
Change From Baseline in Medical Outcomes Study Short Form 36 (SF-36): Reported Health Transition Score
Subject-rated measure of health status (36 items): 8 subscale scores (physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, mental health), 2 summary scores (physical component, mental component), and a self-evaluated change in health status. Change from Baseline in SF-36 Health Transition score at each visit. I=much better than 1 year ago; II=somewhat better than 1 year ago; III=about the same as 1 year ago; IV=somewhat worse than 1 year ago; V=much worse than 1 year ago
Time frame: Baseline, Month 15, Month 27, Month 39
Change From Baseline in BORG Dyspnea Score
BORG Dyspnea score: change from core study Baseline. Subject rating of maximum degree of dyspnea experienced at any time during the 6-Minute Walk Test. Range: 0 (no breathlessness at all) to 10 (maximum breathlessness).
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24, Month 27, Month 30, Month 33, Month 36
Change in Epoprostenol Dose From Baseline Maintained for 6 Months
Number of subjects with changes in Epoprostenol dose from baseline maintained continuously for 6 months. Increased = Epoprostenol dose continuously more than 20% greater than core study Baseline for at least 6 months. Decrease = Epoprostenol dose continuously more than 20% less than core study Baseline for at least 6 months. No change = Epoprostenol dose change met neither Increase or Decrease criteria. Stopped = Epoprostenol dose stopped for at least 6 months.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Month 9, and at 3-month intervals through Month 69
| Milestone | Placebo: Core Study / Sildenafil: Extension Study | Sildenafil: Core Study / Sildenafil: Extension Study |
|---|---|---|
| Started | 133 | 134 |
| Treated | 131 | 134 |
| Completed | 108 | 122 |
| Not completed | 25 | 12 |
| Withdrew: Death | 3 | 0 |
| Withdrew: Adverse event | 12 | 6 |
| Withdrew: Lack of efficacy | 2 | 3 |
| Withdrew: Reason unspecified | 5 | 3 |
| Withdrew: Subject defaulted | 1 | 0 |
| Withdrew: Randomized but not treated | 2 | 0 |
| Milestone | Placebo: Core Study / Sildenafil: Extension Study | Sildenafil: Core Study / Sildenafil: Extension Study |
|---|---|---|
| Started | 115 | 127 |
| Treated | 115 | 127 |
| Completed | 53 | 56 |
| Not completed | 62 | 71 |
| Withdrew: Death | 24 | 28 |
| Withdrew: Adverse event | 14 | 14 |
| Withdrew: Lack of efficacy | 5 | 1 |
| Withdrew: Reason unspecified | 12 | 19 |
| Withdrew: Withdrawal by subject | 7 | 9 |
Number of subjects with changes in Epoprostenol dose from baseline maintained continuously for 6 months. Increased = Epoprostenol dose continuously more than 20% greater than core study Baseline for at least 6 months. Decrease = Epoprostenol dose continuously more than 20% less than core study Baseline for at least 6 months. No change = Epoprostenol dose change met neither Increase or Decrease criteria. Stopped = Epoprostenol dose stopped for at least 6 months.
| participants | All Subjects |
|---|---|
| Week 4: >20% Increase | 0 |
| Week 4: No Change | 0 |
| Week 4: >20% Decrease | 0 |
| Week 4: Stopped | 0 |
| Week 4: Missing | 13 |
| Week 8: >20% Increase | 0 |
| Week 8: No Change | 0 |
| Week 8: >20% Decrease | 0 |
| Week 8: Stopped | 0 |
| Week 8: Missing | 11 |
| Week 12: >20% Increase | 0 |
| Week 12: No Change | 0 |
| Week 12: >20% Decrease | 0 |
| Week 12: Stopped | 0 |
| Week 12: Missing | 14 |
| Week 16: >20% Increase | 0 |
| Week 16: No Change | 0 |
| Week 16: >20% Decrease | 0 |
| Week 16: Stopped | 0 |
| Week 16: Missing | 199 |
| Week 20: >20% Increase | 0 |
| Week 20: No Change | 0 |
| Week 20: >20% Decrease | 0 |
| Week 20: Stopped | 0 |
| Week 20: Missing | 186 |
| Week 24: >20% Increase | 0 |
| Week 24: No Change | 0 |
| Week 24: >20% Decrease | 0 |
| Week 24: Stopped | 0 |
| Week 24: Missing | 190 |
| Month 9: >20% Increase | 0 |
| Month 9: No Change | 0 |
| Month 9: >20% Decrease | 0 |
| Month 9: Stopped | 0 |
| Month 9: Missing | 174 |
| Month 12: >20% Increase | 4 |
| Month 12: No Change | 162 |
| Month 12: >20% Decrease | 9 |
| Month 12: Stopped | 0 |
| Month 12: Missing | 0 |
| Month 15: >20% Increase | 5 |
| Month 15: No Change | 130 |
| Month 15: >20% Decrease | 20 |
| Month 15: Stopped | 1 |
| Month 15: Missing | 0 |
| Month 18: >20% Increase | 10 |
| Month 18: No Change | 109 |
| Month 18: >20% Decrease | 27 |
| Month 18: Stopped | 1 |
| Month 18: Missing | 0 |
| Month 21: >20% Increase | 10 |
| Month 21: No Change | 105 |
| Month 21: >20% Decrease | 27 |
| Month 21: Stopped | 2 |
| Month 21: Missing | 0 |
| Month 24: >20% Increase | 15 |
| Month 24: No Change | 93 |
| Month 24: >20% Decrease | 24 |
| Month 24: Stopped | 2 |
| Month 24: Missing | 0 |
| Month 27: >20% Increase | 18 |
| Month 27: No Change | 87 |
| Month 27: >20% Decrease | 23 |
| Month 27: Stopped | 3 |
| Month 27: Missing | 0 |
| Month 30: >20% Increase | 19 |
| Month 30: No Change | 78 |
| Month 30: >20% Decrease | 23 |
| Month 30: Stopped | 3 |
| Month 30: Missing | 0 |
| Month 33: >20% Increase | 18 |
| Month 33: No Change | 76 |
| Month 33: >20% Decrease | 22 |
| Month 33: Stopped | 2 |
| Month 33: Missing | 0 |
| Month 36: >20% Increase | 20 |
| Month 36: No Change | 66 |
| Month 36: >20% Decrease | 19 |
| Month 36: Stopped | 4 |
| Month 36: Missing | 0 |
| Month 39: >20% Increase | 19 |
| Month 39: No Change | 55 |
| Month 39: >20% Decrease | 19 |
| Month 39: Stopped | 5 |
| Month 39: Missing | 0 |
| Month 42: >20% Increase | 19 |
| Month 42: No Change | 55 |
| Month 42: >20% Decrease | 18 |
| Month 42: Stopped | 5 |
| Month 42: Missing | 0 |
| Month 45: >20% Increase | 24 |
| Month 45: No Change | 51 |
| Month 45: >20% Decrease | 15 |
| Month 45: Stopped | 4 |
| Month 45: Missing | 0 |
| Month 48: >20% Increase | 23 |
| Month 48: No Change | 38 |
| Month 48: >20% Decrease | 17 |
| Month 48: Stopped | 5 |
| Month 48: Missing | 0 |
| Month 51: >20% Increase | 17 |
| Month 51: No Change | 33 |
| Month 51: >20% Decrease | 14 |
| Month 51: Stopped | 3 |
| Month 51: Missing | 0 |
| Month 54: >20% Increase | 14 |
| Month 54: No Change | 31 |
| Month 54: >20% Decrease | 14 |
| Month 54: Stopped | 5 |
| Month 54: Missing | 0 |
| Month 57: >20% Increase | 12 |
| Month 57: No Change | 27 |
| Month 57: >20% Decrease | 12 |
| Month 57: Stopped | 4 |
| Month 57: Missing | 0 |
| Month 60: >20% Increase | 12 |
| Month 60: No Change | 22 |
| Month 60: >20% Decrease | 11 |
| Month 60: Stopped | 2 |
| Month 60: Missing | 0 |
| Month 63: >20% Increase | 6 |
| Month 63: No Change | 21 |
| Month 63: >20% Decrease | 4 |
| Month 63: Stopped | 1 |
| Month 63: Missing | 0 |
| Month 66: >20% Increase | 4 |
| Month 66: No Change | 15 |
| Month 66: >20% Decrease | 2 |
| Month 66: Stopped | 1 |
| Month 66: Missing | 0 |
| Month 69: >20% Increase | 4 |
| Month 69: No Change | 9 |
| Month 69: >20% Decrease | 1 |
| Month 69: Stopped | 0 |
| Month 69: Missing | 0 |
Yearly survival status: number of subjects who survived, discontinued, and died. Analysis includes post-treatment visit data from subjects who discontinued study treatment. Time to death was taken relative to the first dose of study treatment in A1481141, and was censored on the last day the subject was known to be alive in A1481141 or A1481153.
| participants | All Subjects |
|---|---|
| 1 year: Deaths | 24 |
| 1 Year: Survived 1 Year of Study | 205 |
| 1 Year: Discontinued before 1 Year of Study | 36 |
| 2 Years: Deaths | 48 |
| 2 Years: Survived 2 Years of Study | 169 |
| 2 Years: Discontinued before 2 Years of Study | 48 |
| 3 Years: Deaths | 64 |
| 3 Years: Survived 3 Years of Study | 133 |
| 3 Years: Discontinued before 3 Years of Study | 68 |
| 4 Years: Deaths | 71 |
| 4 Years: Survived 4 Years of Study | 88 |
| 4 Years: Discontinued before 4 Years of Study | 75 |
| 4 Years: Ongoing for Less than Timepoint | 26 |
| 5 Years: Deaths | 82 |
| 5 Years: Survived 5 Years of Study | 29 |
| 5 Years: Discontinued before 5 Years of Study | 74 |
| 5 Years: Ongoing for Less than Timepoint | 78 |
Number of subjects with categorized change in 6-minute walking distance. Distance that a subject could walk in 6-minutes at a comfortable pace with as many breaks as needed. Performed as close to trough levels of sildenafil as possible (just before dosing; at least 4 hours after the previous dose of study drug). Scores for categorized changes for missing visits were imputed as the worse score of its non-missing neighbors. If a visit was missing and there was no subsequent score, the score was coded to missing.
| participants | Placebo/Sildenafil | Sildenafil/Sildenafil |
|---|---|---|
| 1 Year: >= 60 m Improvement | 27 | 46 |
| 1 Year: 60 - 30 m Improvement | 20 | 26 |
| 1 Year: 30 - 0 m Improvement | 23 | 15 |
| 1 Year: 0 - 30 m Worsening | 12 | 10 |
| 1 Year: 30 - 60 m Worsening | 6 | 6 |
| 1 Year: > 60 m Worsening | 6 | 6 |
| 1 Year: Discontinued | 22 | 14 |
| 1 Year: Died | 14 | 10 |
| 1 Year: Missing | 1 | 1 |
| 2 Year: >= 60 m Improvement | 23 | 44 |
| 2 Year: 60 - 30 m Improvement | 16 | 10 |
| 2 Year: 30 - 0 m Improvement | 15 | 8 |
| 2 Year: 0 - 30 m Worsening | 18 | 9 |
| 2 Year: 30 - 60 m Worsening | 2 | 7 |
| 2 Year: > 60 m Worsening | 7 | 7 |
| 2 Year: Discontinued | 25 | 23 |
| 2 Year: Died | 24 | 24 |
| 2 Year: Missing | 1 | 2 |
| 3 Year: >= 60 m Improvement | 22 | 29 |
| 3 Year: 60 - 30 m Improvement | 9 | 10 |
| 3 Year: 30 - 0 m Improvement | 10 | 8 |
| 3 Year: 0 - 30 m Worsening | 15 | 5 |
| 3 Year: 30 - 60 m Worsening | 3 | 7 |
| 3 Year: > 60 m Worsening | 5 | 8 |
| 3 Year: Discontinued | 35 | 33 |
| 3 Year: Died | 31 | 33 |
| 3 Year: Missing | 1 | 1 |
Pulmonary hypertension (PH) criteria: Class I: PH without limitation of physical activity (PA) (no undue dyspnea, fatigue, chest pain, near syncope); Class II: PH with slight limitation in PA, comfortable at rest, ordinary PA causes undue dyspnea, fatigue, chest pain, near syncope; Class III: PH with marked limitation in PA, comfortable at rest, less than ordinary activity causes undue dyspnea, fatigue, chest pain or syncope; Class IV: PH with inability to carry out PA without symptoms, signs of right heart failure, dyspnea or fatigue may be present at rest, discomfort increased by any PA.
| participants | Placebo/Sildenafil | Sildenafil/Sildenafil |
|---|---|---|
| 1 Year: Improved 2 Classes | 2 | 3 |
| 1 Year: Improved 1 Class | 27 | 46 |
| 1 Year: No Change | 59 | 57 |
| 1 Year: Worsened 1 Class | 7 | 3 |
| 1 Year: Worsened 2 Classes | 0 | 1 |
| 1 Year: Discontinued | 22 | 14 |
| 1 Year: Died | 14 | 10 |
| 2 Year: Improved 2 Classes | 1 | 4 |
| 2 Year: Improved 1 Class | 24 | 31 |
| 2 Year: No Change | 50 | 47 |
| 2 Year: Worsened 1 Class | 7 | 5 |
| 2 Year: Worsened 2 Classes | 0 | 0 |
| 2 Year: Discontinued | 25 | 23 |
| 2 Year: Died | 24 | 24 |
| 3 Year: Improved 2 Classes | 1 | 4 |
| 3 Year: Improved 1 Class | 21 | 21 |
| 3 Year: No Change | 39 | 37 |
| 3 Year: Worsened 1 Class | 3 | 6 |
| 3 Year: Worsened 2 Classes | 1 | 0 |
| 3 Year: Discontinued | 35 | 33 |
| 3 Year: Died | 31 | 33 |
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores = better health status. Change from baseline = score at observation minus score at baseline.
| scores on scale | Placebo/Sildenafil | Sildenafil/Sildenafil |
|---|---|---|
| Month 15: Physical Functioning Score (n=59, 83) | 10.5 (6.0 to 15.1) | 14.8 (10.1 to 19.4) |
| Month 27: Physical Functioning Score (n=60, 62) | 9.7 (5.0 to 14.4) | 12.5 (7.1 to 17.9) |
| Month 39: Physical Functioning Score (n=42, 47) | 8.9 (1.9 to 15.9) | 14.0 (7.6 to 20.4) |
| Month 15: Role Limitations (phys health)(n=59, 82) | 15.7 (4.9 to 26.4) | 14.2 (3.3 to 25.2) |
| Month 27: Role Limitations (phys health)(n=60, 62) | 4.6 (-8.3 to 17.5) | 2.6 (-9.8 to 14.9) |
| Month 39: Role Limitations (phys health)(n=42, 47) | 4.2 (-11.0 to 19.4) | 5.1 (-9.8 to 20.1) |
| Month 15: Bodily Pain Score (n=59, 82) | 10.4 (4.5 to 16.3) | 5.9 (0.3 to 11.5) |
| Month 27: Bodily Pain Score (n=60, 62) | -0.1 (-6.4 to 6.3) | 4.0 (-1.8 to 9.9) |
| Month 39: Bodily Pain Score (n=42, 46) | -4.9 (-13.2 to 3.4) | 3.5 (-3.4 to 10.5) |
| Month 15: General Health Score (n=59, 83) | -0.2 (-5.5 to 5.2) | 10.1 (5.4 to 14.7) |
| Month 27: General Health Score (n=60, 62) | 2.7 (-2.6 to 8.1) | 6.9 (2.0 to 11.7) |
| Month 39: General Health Score (n=41, 47) | 3.1 (-2.6 to 8.7) | 3.4 (-2.8 to 9.7) |
| Month 15: Vitality Score (n=59, 83) | 5.0 (-0.3 to 10.4) | 8.9 (3.7 to 14.0) |
| Month 27: Vitality Score (n=60, 62) | 5.7 (0.8 to 10.5) | 7.2 (2.0 to 12.3) |
| Month 39: Vitality Score (n=42, 47) | 6.9 (0.3 to 13.6) | 5.2 (-0.7 to 11.1) |
| Month 15: Social Functioning Score (n=59, 83) | 5.9 (-2.2 to 14.1) | 5.1 (-1.2 to 11.5) |
| Month 27: Social Functioning Score (n=60, 63) | 6.7 (-0.6 to 13.9) | 1.4 (-6.5 to 9.3) |
| Month 39: Social Functioning Score (n=42, 47) | 2.4 (-5.9 to 10.6) | -0.8 (-9.3 to 7.7) |
| Month 15: Role Limitations (Emotional) (n=59, 82) | 1.7 (-10.1 to 13.5) | 1.2 (-8.8 to 11.3) |
| Month 27: Role Limitations (Emotional) (n=60, 62) | -1.7 (-13.4 to 10.0) | -7.0 (-18.1 to 4.1) |
| Month 39: Role Limitations (Emotional) (n=42, 47) | 3.2 (-10.7 to 17.1) | 2.1 (-7.5 to 11.8) |
| Month 15: Mental Health Score (n=59, 83) | 0.5 (-3.9 to 4.9) | 3.3 (-1.1 to 7.7) |
| Month 27: Mental Health Score (n=60, 62) | 0.9 (-3.4 to 5.1) | 0.1 (-4.6 to 4.8) |
| Month 39: Mental Health Score (n=42, 47) | 0.8 (-4.9 to 6.6) | 3.7 (-1.9 to 9.3) |
EQ-5D: subject rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
| scores on scale | Placebo/Sildenafil | Sildenafil/Sildenafil |
|---|---|---|
| Month 15 (n=58, 78) | 0.0505 (-0.0078 to 0.1087) | 0.0473 (-0.0065 to 0.1012) |
| Month 27 (n=56, 60) | 0.0489 (-0.0146 to 0.1123) | 0.0483 (-0.0272 to 0.1237) |
| Month 39 (n=40, 43) | -0.0278 (-0.1253 to 0.0697) | 0.0770 (0.0013 to 0.1526) |
EQ-5D: subject rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
| scores on scale | Placebo/Sildenafil | Sildenafil/Sildenafil |
|---|---|---|
| Month 15 (n=57, 81) | 6.8 (2.4 to 11.1) | 12.8 (8.3 to 17.3) |
| Month 27 (n=55, 60) | 5.5 (1.7 to 9.3) | 11.2 (5.9 to 16.4) |
| Month 39 (n=40, 41) | 4.7 (-0.2 to 9.5) | 11.5 (5.5 to 17.5) |
Subject-rated measure of health status (36 items): 8 subscale scores (physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, mental health), 2 summary scores (physical component, mental component), and a self-evaluated change in health status. Change from Baseline in SF-36 Health Transition score at each visit. I=much better than 1 year ago; II=somewhat better than 1 year ago; III=about the same as 1 year ago; IV=somewhat worse than 1 year ago; V=much worse than 1 year ago
| participants | Placebo/Sildenafil | Sildenafil/Sildenafil |
|---|---|---|
| BL I; Month 15: I | 2 | 9 |
| BL I; Month 15: II | 5 | 4 |
| BL I; Month 15: III | 5 | 2 |
| BL I; Month 15: IV | 0 | 1 |
| BL I; Month 15: V | 0 | 0 |
| BL II; Month 15: I | 7 | 5 |
| BL II; Month 15: II | 9 | 12 |
| BL II; Month 15: III | 3 | 7 |
| BL II; Month 15: IV | 1 | 2 |
| BL II; Month 15: V | 0 | 0 |
| BL III; Month 15: I | 3 | 4 |
| BL III; Month 15: II | 6 | 8 |
| BL III; Month 15: III | 11 | 7 |
| BL III; Month 15: IV | 0 | 2 |
| BL III; Month 15: V | 0 | 0 |
| BL IV; Month 15: I | 2 | 5 |
| BL IV; Month 15: II | 0 | 3 |
| BL IV; Month 15: III | 2 | 3 |
| BL IV; Month 15: IV | 1 | 4 |
| BL IV; Month 15: V | 1 | 0 |
| BL V; Month 15: I | 0 | 1 |
| BL V; Month 15: II | 0 | 3 |
| BL V; Month 15: III | 0 | 1 |
| BL V; Month 15: IV | 0 | 0 |
| BL V; Month 15: V | 0 | 0 |
| Month 15: Missing Data | 73 | 51 |
| BL I; Month 27: I | 4 | 2 |
| BL I; Month 27: II | 2 | 6 |
| BL I; Month 27: III | 2 | 2 |
| BL I; Month 27: IV | 3 | 0 |
| BL I; Month 27: V | 0 | 0 |
| BL II; Month 27: I | 4 | 3 |
| BL II; Month 27: II | 9 | 7 |
| BL II; Month 27: III | 8 | 7 |
| BL II; Month 27: IV | 1 | 3 |
| BL II; Month 27: V | 0 | 0 |
| BL III; Month 27: I | 3 | 5 |
| BL III; Month 27: II | 7 | 6 |
| BL III; Month 27: III | 9 | 7 |
| BL III; Month 27: IV | 2 | 3 |
| BL III; Month 27: V | 0 | 0 |
| BL IV; Month 27: I | 1 | 1 |
| BL IV; Month 27: II | 1 | 3 |
| BL IV; Month 27: III | 1 | 3 |
| BL IV; Month 27: IV | 1 | 3 |
| BL IV; Month 27: V | 0 | 0 |
| BL V; Month 27: I | 0 | 1 |
| BL V; Month 27: II | 0 | 0 |
| BL V; Month 27: III | 0 | 1 |
| BL V; Month 27: IV | 0 | 0 |
| BL V; Month 27: V | 0 | 0 |
| Month 27: Missing Data | 73 | 71 |
| BL I; Month 39: I | 1 | 2 |
| BL I; Month 39: II | 2 | 4 |
| BL I; Month 39: III | 3 | 4 |
| BL I; Month 39: IV | 1 | 1 |
| BL I; Month 39: V | 0 | 0 |
| BL II; Month 39: I | 4 | 5 |
| BL II; Month 39: II | 6 | 3 |
| BL II; Month 39: III | 6 | 6 |
| BL II; Month 39: IV | 3 | 1 |
| BL II; Month 39: V | 0 | 0 |
| BL III; Month 39: I | 2 | 3 |
| BL III; Month 39: II | 3 | 3 |
| BL III; Month 39: III | 8 | 6 |
| BL III; Month 39: IV | 1 | 1 |
| BL III; Month 39: V | 0 | 0 |
| BL IV; Month 39: I | 0 | 0 |
| BL IV; Month 39: II | 1 | 0 |
| BL IV; Month 39: III | 0 | 2 |
| BL IV; Month 39: IV | 1 | 4 |
| BL IV; Month 39: V | 0 | 0 |
| BL V; Month 39: I | 0 | 1 |
| BL V; Month 39: II | 0 | 0 |
| BL V; Month 39: III | 0 | 1 |
| BL V; Month 39: IV | 0 | 0 |
| BL V; Month 39: V | 0 | 0 |
| Month 39: Missing Data | 89 | 87 |
BORG Dyspnea score: change from core study Baseline. Subject rating of maximum degree of dyspnea experienced at any time during the 6-Minute Walk Test. Range: 0 (no breathlessness at all) to 10 (maximum breathlessness).
| scores on scale | Placebo/Sildenafil | Sldenafil/Sildenafil |
|---|---|---|
| Week 4 (n=112, 120) | 0.0 (-9.0 to 10.0) | 0.0 (-6.0 to 4.0) |
| Week 8 (n=106, 113) | 0.0 (-8.0 to 9.0) | 0.0 (-6.0 to 4.0) |
| Week 12 (n=102, 108) | 0.0 (-6.0 to 4.0) | 0.0 (-7.0 to 4.0) |
| Week 16 (n=95, 106) | 0.0 (-6.0 to 9.0) | 0.0 (-7.0 to 6.0) |
| Week 20 (n=80, 96) | 0.0 (-8.0 to 6.0) | 0.0 (-7.0 to 4.0) |
| Week 24 (n=91, 105) | 0.0 (-7.0 to 4.0) | 0.0 (-8.0 to 4.0) |
| Month 9 (n=75, 98) | 0.0 (-4.0 to 4.0) | 0.0 (-8.0 to 5.0) |
| Month 12 (n=72, 90) | 0.0 (-6.0 to 4.0) | 0.0 (-7.0 to 4.0) |
| Month 15 (n=75, 91) | 0.0 (-6.0 to 3.0) | 0.0 (-9.0 to 4.0) |
| Month 18 (n=67, 74) | 0.0 (-7.0 to 3.0) | 0.0 (-8.0 to 4.0) |
| Month 21 (n=67, 79) | 0.0 (-6.0 to 3.0) | 0.0 (-7.0 to 4.0) |
| Month 24 (n=68, 60) | 0.0 (-6.0 to 7.0) | 0.0 (-7.0 to 5.0) |
| Month 27 (n=67, 69) | 0.0 (-4.0 to 4.0) | 0.0 (-7.0 to 3.0) |
| Month 30 (n=55, 68) | 0.0 (-7.0 to 7.0) | 0.0 (-8.0 to 5.0) |
| Month 33 (n=62, 65) | 0.0 (-4.0 to 7.0) | 0.0 (-7.0 to 6.0) |
| Month 36 (n=51, 62) | 0.0 (-7.0 to 5.0) | 0.0 (-7.0 to 5.0) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/Sildenafil | — | 93/115 (80.9%) | 115/115 (100%) |
| Sildenafil/Sildenafil | — | 104/134 (77.6%) | 134/134 (100%) |
| Placebo/Discontinued | — | 7/16 (43.8%) | 15/16 (93.8%) |
| Event | Placebo/Sildenafil | Sildenafil/Sildenafil | Placebo/Discontinued |
|---|---|---|---|
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 15/115 | 22/134 | 2/16 |
| Right ventricular failureCardiac disorders | 16/115 | 13/134 | 2/16 |
| Catheter related infectionInfections and infestations | 15/115 | 17/134 | 0/16 |
| Catheter related complicationGeneral disorders | 14/115 | 3/134 | 0/16 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 11/115 | 14/134 | 1/16 |
| Central line infectionInfections and infestations | 8/115 | 13/134 | 0/16 |
| PneumoniaInfections and infestations | 11/115 | 12/134 | 0/16 |
| AnaemiaBlood and lymphatic system disorders | 9/115 | 2/134 | 0/16 |
| Chest painGeneral disorders | 9/115 | 3/134 | 0/16 |
| SepsisInfections and infestations | 9/115 | 6/134 | 0/16 |
| Event | Placebo/Sildenafil | Sildenafil/Sildenafil | Placebo/Discontinued |
|---|---|---|---|
| HeadacheNervous system disorders | 75/115 | 91/134 | 3/16 |
| DiarrhoeaGastrointestinal disorders | 54/115 | 64/134 | 5/16 |
| NauseaGastrointestinal disorders | 48/115 | 63/134 | 4/16 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 44/115 | 62/134 | 2/16 |
| DizzinessNervous system disorders | 39/115 | 59/134 | 5/16 |
| FatigueGeneral disorders | 44/115 | 56/134 | 4/16 |
| Upper respiratory tract infectionInfections and infestations | 39/115 | 54/134 | 1/16 |
| FlushingVascular disorders | 35/115 | 45/134 | 2/16 |
| Oedema peripheralGeneral disorders | 37/115 | 38/134 | 1/16 |
| CoughRespiratory, thoracic and mediastinal disorders | 37/115 | 40/134 | 0/16 |
| Age, Customized(participants) | Placebo/Sildenafil | Sildenafil/Sildenafil | Total |
|---|---|---|---|
| 18 to 44 years | 47 | 54 | 101 |
| 45 to 64 years | 73 | 64 | 137 |
| >= 65 years | 11 | 16 | 27 |
| Sex: Female, Male(Participants) | Placebo/Sildenafil | Sildenafil/Sildenafil | Total |
|---|---|---|---|
| Female | 102 | 110 | 212 |
| Male | 29 | 24 | 53 |
The record gives a start of Jul 2003 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →